ACTU
HealthcareActuate Therapeutics, Inc. Common stock
$6.34
+$0.31 (+5.14%)
Jan 5, 2026
Price History (1Y)
Analysis
Actuate Therapeutics, Inc. Common stock operates in the Healthcare sector, specifically within the Biotechnology industry. With a market capitalization of $147.36M and 10 employees, it is a relatively small company. The company's financial health is concerning. Actuate Therapeutics has reported net income losses with a Net Income (TTM) of -$24,119,988. Additionally, its profitability margins are at or near zero: Gross Margin is 0.0%, Operating Margin is 0.0%, and Profit Margin is 0.0%. Returns on equity and assets are also negative, with Return on Equity at -296.0% and Return on Assets at -95.2%. The company's valuation metrics paint a mixed picture. The P/E Ratio (TTM) is 17.61, while the Forward P/E is -6.08, which may be influenced by the recent net income losses. Other valuation metrics such as Price to Book and EV/EBITDA are not available for comparison.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Visit website →Key Statistics
- Market Cap
- $147.36M
- P/E Ratio
- 17.61
- 52-Week High
- $11.99
- 52-Week Low
- $5.47
- Avg Volume
- 70.87K
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 10